GlassScriptPhysician profile
Joseph L Buono
NPI 1932193448
$17,298.65
in general payments reported to CMS, 2019-2025
46 companies · $2,866 in 2025
The $2,866 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,521 · 2020: $1,940 · 2021: $2,048 · 2022: $2,618 · 2023: $3,100 · 2024: $3,205 · 2025: $2,866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,171.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,129.52 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $2,338.88 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $1,481.12 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $1,374.54 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $1,022.21 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $849.78 | 2019-2025 | |
| Pfizer INC. | $784.86 | 2019-2025 | |
| Amarin Pharma, INC. | $591.27 | 2019-2022 | |
| Esperion Therapeutics, INC. | $568.47 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $471.98 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $446.69 | 2019-2025 | Trintellix |
| Almatica Pharma LLC | $351.26 | 2021-2025 | Loreev Xr, Teriparatide |
| Merck Sharp & Dohme LLC | $350.93 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.36 | 2019-2025 | Jardiance |
| Axsome Therapeutics, INC. | $280.50 | 2023-2025 | Auvelity, Symbravo |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $255.06 | 2019-2025 | Zoryve |
| Exact Sciences Corporation | $227.65 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $225.35 | 2022 | |
| Allergan, INC. | $224.80 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $219.66 | 2022-2024 | Caplyta |
| Astellas Pharma US INC | $205.10 | 2019-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $191.31 | 2019-2020 | |
| Genzyme Corporation | $170.00 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $154.07 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $127.40 | 2020-2025 | Cobenfy, Camzyos, Eliquis |
| Idorsia Pharmaceuticals US INC | $105.20 | 2022-2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $98.26 | 2023 | |
| Abbott Laboratories | $92.23 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Intra-Sana Laboratories | $72.29 | 2024-2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Eisai INC. | $65.04 | 2020-2022 | |
| Agios Pharmaceuticals, INC. | $64.17 | 2025 | Pyrukynd |
| Otsuka America Pharmaceutical, INC. | $62.49 | 2022-2023 | Rexulti |
| Arbor Pharmaceuticals, INC. | $59.63 | 2019-2021 | |
| Hikma Pharmaceuticals USA | $57.09 | 2019-2023 | Ryaltris |
| Currax Pharmaceuticals LLC | $48.11 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $45.37 | 2021 | |
| Amgen INC. | $28.34 | 2023 | Repatha, Otezla |
| Vistapharm, INC. | $27.75 | 2021 | |
| Dexcom, INC. | $22.03 | 2024 | Dexcom G6 Transmitter |
| Alkermes, INC. | $20.83 | 2024 | Lybalvi |
| Corium, LLC | $19.74 | 2023-2025 | Azstarys |
| Cumberland Pharmaceuticals, INC. | $19.62 | 2022 | |
| Genentech USA, INC. | $19.17 | 2020 | |
| Mannkind Corporation | $16.97 | 2019 | |
| Phathom Pharmaceuticals, INC. | $15.29 | 2024 | Voquezna |
| Horizon Therapeutics Plc | $11.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Buono listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.